

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR.	ATTORNEY DOCKET NO	CONFIRMATION NO.	
09/943,054	08/30/2001	Sciichi Araki	109536-161	8743	
23483 7	590 08/09/2004		EXAMINER		
WILMER CUTLER PICKERING HALE AND DORR LLP			WEDDINGTON, KEVIN E		
60 STATE STREET BOSTON, MA 02109			ART UNIT	PAPER NUMBER	
Boston, mi	. 02103		1614		
				DATE MAILED: 08/09/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		<del></del>
	Application No.	Applicant(s)
	09/943,054	ARAKI ET AL.
Office Action Summary	Examiner	Art Unit
	Kevin E. Weddington	1614
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period or  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ti y within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS fron e, cause the application to become ABANDONE	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1)⊠ Responsive to communication(s) filed on <u>21 Ju</u>	uly 2004.	
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This	action is non-final.	
3) Since this application is in condition for alloward closed in accordance with the practice under E		
Disposition of Claims		
4) Claim(s) <u>1-54</u> is/are pending in the application 4a) Of the above claim(s) is/are withdraw		
5) Claim(s) <u>1-8</u> is/are allowed.	nom concluctuation.	
6)⊠ Claim(s) <u>9-54</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/o	r election requirement.	
Application Papers		
9)☐ The specification is objected to by the Examine	er.	
10)☐ The drawing(s) filed on is/are: a)☐ acc	epted or b)□ objected to by the	Examiner.
Applicant may not request that any objection to the		, ,
Replacement drawing sheet(s) including the correct		
11)☐ The oath or declaration is objected to by the Ex	caminer. Note the attached Office	e Action or form PTO-152.
Priority under 35 U.S.C. § 119		
<ul> <li>12) Acknowledgment is made of a claim for foreign</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents</li> <li>2. Certified copies of the priority documents</li> </ul>	s have been received.	
3. ☐ Copies of the certified copies of the prior	rity documents have been receiv	ed in this National Stage
application from the International Bureau	u (PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list	of the certified copies not receive	ed.
Attachment(s)		
Notice of References Cited (PTO-892)	4) Interview Summary	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	Paper No(s)/Mail D  5) Notice of Informal F	ate Patent Application (PTO-152)
Paper No(s)/Mail Date	6) Other:	,, ,

Application/Control Number: 09/943,054

Art Unit: 1614

Claims 1-54 are presented for examination.

Applicants' request for continued examination filed July 21, 2004 has been received and entered.

Again, the preliminary amendment filed August 30, 2001 has been received and entered, however, the amendment does not comply with 37 CFR 1.173(b) as all added claims must be entirely underlined.

Applicants' amendments filed March 10, 2003 and July 21, 2004 have been received, but not entered as they do not comply with 37 CFR 1.173(b).

Accordingly, the rejections made under 35 USC 112, first paragraph and 35 USC 101 double patenting as set forth in the previous Office action at pages 3-5 are hereby withdrawn.

The applicants send in a copy of the Offer to Surrender Declaration that was executed on September 7, 2001, so the requirement has been fulfilled.

## Allowable Subject Matter

Claims 1-8 are allowable.

## **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a

Application/Control Number: 09/943,054

Art Unit: 1614

nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 11, 21, 31 and 48-54 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 2 of U.S. Patent No. 5,814,632. Although the conflicting claims are not identical, they are not patentably distinct from each other because the present application teaches a method for treating a patient with sepsis with riboflavin and/or riboflavin derivatives, and the patented application teaches a method for the treatment of disease selected from the group consisting of: which includes sepsis with riboflavin and/or a riboflavin derivative too. Also note the patented application dosage range for the active ingredients is 0.5-500 mg/kg and the present application range of 0.1 to 500 mg/kg is totally encompassed by the range of the patented application.

Claims 11, 21, 31 and 48-54 are not allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin E. Weddington whose telephone number is (571) 272-0587. The examiner can normally be reached on 11:00 am-7: 30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571) 272-0953.

Application/Control Number: 09/943,054

Art Unit: 1614

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kevin E. Weddington Primary Examiner Art Unit 1614

K. Weddington August 4, 2004